The availability of this mouse model of MVID will not only contribute to the characterization of the molecular pathological mechanisms downstream of Myosin Vb leading to novel therapeutic approaches, but also provides an ideal system to preclinically test different treatment options. This evidence concerns the gene MYO5B and microvillus inclusion disease.